Compare ARBE & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBE | LONA |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | Israel | United States |
| Employees | 144 | 19 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 81.5M |
| IPO Year | N/A | N/A |
| Metric | ARBE | LONA |
|---|---|---|
| Price | $0.68 | $7.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.38 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.8M | 36.6K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $363.94 | N/A |
| Revenue Next Year | $286.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $4.21 |
| 52 Week High | $2.88 | $14.21 |
| Indicator | ARBE | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 39.63 |
| Support Level | $0.65 | $7.00 |
| Resistance Level | $0.90 | $9.78 |
| Average True Range (ATR) | 0.06 | 0.71 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 6.52 | 12.24 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, Hong Kong, USA, Israel, Switzerland, Italy, and others.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.